

- H2* 47. A pharmaceutical composition containing an anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.
48. A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 and a human constant region selected from the group consisting of a human gamma -1 constant region and a human gamma -3 constant region.
- not H3* 49. A chimeric anti-human CD23 antibody wherein the variable light domain comprises the polypeptide encoded by SEQ ID NO: 3 and the variable heavy domain comprises the polypeptide encoded by SEQ ID NO: 4 with the exception that the asparagine colon at position 75 is replaced with a lysine.
50. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -1 constant region.
51. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -3 constant region.
52. The anti-human CD23 antibody according to claim 49 which comprises gamma -1 constant region.
53. The anti-human CD23 antibody according to claim 49 which comprises a human gamma -3 constant region.
- On 1
Conte
not H4* 54. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.
55. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.
56. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.
57. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.
58. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.
59. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.
60. A pharmaceutical composition comprising an anti-human CD23 antibody according to claim 54 and a pharmaceutically acceptable carrier.